Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROXYMO-ADVANCE cotadutide in non-cirrhotic NASH with fibrosis
jRCT2051220031Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial of cotadutide in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of cotadutide and Incidence and titer of anti-drug antibodies (ADAs). Started Nov 2022; status: completed.
02
Drugs
cotadutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on jRCT2051220031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220031.